Gut Microbiome Profiling in Patients With Chronic Heart Failure
NCT ID: NCT06361524
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
150 participants
OBSERVATIONAL
2018-08-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. How does the gut microbiome and its interactions with the host change over time in adults with chronic heart failure?
2. How do these changes relate to heart failure disease severity and complications?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction
NCT02728154
The Gut Microbiota and Metabolites in HFpEF
NCT06645535
Cardiometabolic evalUation REgistry of Heart Failure
NCT06939985
Cohort Study of Chronic Heart Failure
NCT05960890
Cohort Study of Chronic Heart Failure
NCT06092658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart failure
Adults with heart failure with reduced ejection fraction; no intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-ischemic cardiomyopathy
* Body mass index (BMI) 18-40 kg/m2
Exclusion Criteria
* Advanced kidney disease
* Cirrhosis
* Significant gastrointestinal disease including any history of inflammatory bowel disease
* History of extensive bowel resection
* Active malignancy or systemic chemotherapy within the past 12 months
* Active infection
* Current or recent (within 4 weeks) use of systemic antibiotics, commercial probiotics, immunosuppressive or immunomodulatory medications
* Pregnancy/lactation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
American Heart Association
OTHER
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Petra Mamic
Instructor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
856341
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
44967
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.